Andrew Little

Andrew Little is a Senior Scientist II at AbbVie with experience in targeting the RAS signaling pathway in human cancer. Previously, Andrew worked as a Post-Doctoral Fellow at Vanderbilt University where Andrew optimized hits identified from a second-site NMR screen of RAS for ongoing collaborations with industry. Andrew also has experience as a Graduate Student at Boston University where Andrew synthetized natural products related to heterodimers. Furthermore, Andrew has served as a Student Manager at DePaul University Student Center and a Teaching Assistant for undergraduate Organic Chemistry Lab. Overall, Andrew holds a Ph.D. in Organic Chemistry from Boston University and a BS in Chemistry from DePaul University.